Imprimis Pharmaceuticals (NASDAQ: IMMY) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its rivals? We will compare Imprimis Pharmaceuticals to related companies based on the strength of its analyst recommendations, earnings, risk, dividends, institutional ownership, profitability and valuation.

Valuation & Earnings

This table compares Imprimis Pharmaceuticals and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Imprimis Pharmaceuticals $19.94 million -$19.08 million -1.78
Imprimis Pharmaceuticals Competitors $284.49 million $33.78 million 82.33

Imprimis Pharmaceuticals’ rivals have higher revenue and earnings than Imprimis Pharmaceuticals. Imprimis Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Imprimis Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Imprimis Pharmaceuticals -60.71% -264.98% -57.30%
Imprimis Pharmaceuticals Competitors -5,307.10% -218.61% -39.64%

Analyst Recommendations

This is a breakdown of current recommendations for Imprimis Pharmaceuticals and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Imprimis Pharmaceuticals 0 0 1 0 3.00
Imprimis Pharmaceuticals Competitors 867 3226 11703 232 2.71

Imprimis Pharmaceuticals currently has a consensus price target of $5.00, suggesting a potential upside of 204.88%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 46.09%. Given Imprimis Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts clearly believe Imprimis Pharmaceuticals is more favorable than its rivals.

Insider and Institutional Ownership

12.7% of Imprimis Pharmaceuticals shares are held by institutional investors. Comparatively, 50.0% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 12.6% of Imprimis Pharmaceuticals shares are held by insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Risk and Volatility

Imprimis Pharmaceuticals has a beta of -0.37, meaning that its share price is 137% less volatile than the S&P 500. Comparatively, Imprimis Pharmaceuticals’ rivals have a beta of 6.16, meaning that their average share price is 516% more volatile than the S&P 500.

Summary

Imprimis Pharmaceuticals rivals beat Imprimis Pharmaceuticals on 8 of the 12 factors compared.

Imprimis Pharmaceuticals Company Profile

Imprimis Pharmaceuticals, Inc. (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases. The Company is also developing Custom Compounding Choice business, which is focused on developing and dispensing a portfolio of non-proprietary compounded drugs for humans and animals in therapeutic areas that may be overlooked by commercial pharmaceutical companies. The Company also offers customizable compounding products that consist of sterile injectable and non-sterile integrative medicine therapies that are used in various therapeutic areas.

Receive News & Ratings for Imprimis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imprimis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.